| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 197 | 2023 |
| Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent J Sánchez-Ramos, CL Dávila-Fajardo, PT Frías, XD Villamarín, ... International journal of cardiology 225, 289-295, 2016 | 62 | 2016 |
| A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed Spanish population HY Tong, CL Dávila-Fajardo, AM Borobia, LJ Martínez-González, ... PLoS One 11 (3), e0150456, 2016 | 28 | 2016 |
| Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries K Blagec, JJ Swen, R Koopmann, KC Cheung, ... PloS one 17 (6), e0268534, 2022 | 26 | 2022 |
| Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention V Fragoulakis, M Bartsakoulia, X Díaz-Villamarín, K Chalikiopoulou, ... The Pharmacogenomics Journal 19 (5), 438-445, 2019 | 26 | 2019 |
| Pharmacogenetics in the treatment of cardiovascular diseases and its current progress regarding implementation in the clinical routine CL Dávila-Fajardo, X Díaz-Villamarín, A Antúnez-Rodríguez, ... Genes 10 (4), 261, 2019 | 18 | 2019 |
| Pharmacogenetic polymorphisms affecting bisoprolol response C Castaño-Amores, X Díaz-Villamarín, AM Pérez-Gutiérrez, ... Biomedicine & Pharmacotherapy 142, 112069, 2021 | 16 | 2021 |
| Genetic variants affecting anti-VEGF drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis X Díaz-Villamarín, D Blánquez-Martínez, A Pozo-Agundo, ... Genes 11 (11), 1335, 2020 | 16 | 2020 |
| Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty X Díaz-Villamarín, CL Dávila-Fajardo, LJ Martínez-González, ... Pharmacogenomics 17 (12), 1327-1338, 2016 | 16 | 2016 |
| Pharmacogenetics of siponimod: A systematic review X Díaz-Villamarín, R Piñar-Morales, FJ Barrero-Hernández, ... Biomedicine & Pharmacotherapy 153, 113536, 2022 | 13 | 2022 |
| Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study MI Koufaki, V Fragoulakis, X Díaz-Villamarín, K Karamperis, A Vozikis, ... Human Genomics 17 (1), 51, 2023 | 12 | 2023 |
| The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention … CL Dávila-Fajardo, J Sánchez-Ramos, X Diaz-Villamarín, ... Data in brief 10, 518-524, 2017 | 6 | 2017 |
| Genetic polymorphisms affecting ranibizumab response in high myopia patients D Blánquez-Martínez, X Díaz-Villamarín, A Antúnez-Rodríguez, ... Pharmaceutics 13 (11), 1973, 2021 | 5 | 2021 |
| Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients D Blánquez-Martínez, X Díaz-Villamarín, S García-Rodríguez, ... Pharmaceutics 14 (8), 1555, 2022 | 4 | 2022 |
| Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation X Díaz-Villamarín, E Fernández-Varón, MCR Romero, JL Callejas-Rubio, ... Biomedicine & Pharmacotherapy 168, 115706, 2023 | 1 | 2023 |
| Implementing CYP2C19 genotyping in our daily clinical practice C Lucia Davila-Fajardo, X Diaz-Villamarin, D Blanquez-Martinez, ... INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 40 (1), 256-257, 2018 | 1 | 2018 |
| CP-086 CD69 A> G (RS11052877) genetic polymorphism on the response to tocilizumab in rheumatoid arthritis patients X Díaz-Villamarín, C Dávila-Fajardo, M González-Medina, ... European Journal of Hospital Pharmacy 24 (Suppl 1), A38-A38, 2017 | 1 | 2017 |
| PKP-022 The KCNMB1 (A> G)(RS703505) genetic variant and the efficacy of tocilizumab in rheumatoid arthritis patients X Díaz-Villamarín, CL Dávila-Fajardo, MDC Gónzalez-Medina, ... European Journal of Hospital Pharmacy 23 (Suppl 1), A188-A188, 2016 | 1 | 2016 |
| PKP-024 The FCGR2A (A> G)(RS1801274) genetic variant and the efficacy of tocilizumab in rheumatoid arthritis patients MDC González-Medina, CL Dávila-Fajardo, MJ Soto-Pino, ... European Journal of Hospital Pharmacy 23 (Suppl 1), A189-A189, 2016 | 1 | 2016 |
| 4CPS-077 Genetic variants affecting bisoprolol response in cardiovascular diseases C Castaño-Amores, P Nieto-Gómez, S Portillo-Haro, MT Nieto, ... European Journal of Hospital Pharmacy 29 (Suppl 1), A53-A53, 2022 | | 2022 |
Luis Javier Martinez-GonzalezResponsable Unidad de Genómica y Genotipado, GENyO在 genyo.es 的电子邮件经过验证
